Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | RARA | P10276 | 2/20 | 0.49 |
| ▸ | RARB | P10826 | 2/20 | 0.49 |
| ▸ | RARG | P13631 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | WDR5 | P61964 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8609153 | 0.83 | EPHX2 (0.51) | NR1H4EPHX2RARARARBRARG | |
| SCHEMBL19818476 | 0.83 | KMT2A (0.54) | NR1H4EPHX2RARARARBRARG | |
| SCHEMBL25950796 | 0.82 | RARA (0.53) | NR1H4EPHX2RARARARBRARG | |
| SCHEMBL8606761 | 0.81 | NR1H4 (0.49) | NR1H4EPHX2RARARARBRARG | |
| SCHEMBL20682518 | 0.81 | TMEM97 (0.53) | NR1H4EPHX2KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL8606766 | 0.81 | POLB (0.52) | NR1H4EPHX2MEN1KMT2ANPC1 | |
| SCHEMBL20206539 | 0.81 | CNR2 (0.52) | NR1H4EPHX2MEN1KMT2ACNR2 | |
| SCHEMBL9453203 | 0.80 | NR1H4 (0.82) | NR1H4EPHX2RARARARBRARG | |
| SCHEMBL19818454 | 0.79 | CNR2 (0.47) | NR1H4EPHX2CNR2CNR1SMN1; SMN2 | |
| SCHEMBL5027170 | 0.79 | MAPT (0.58) | RARARARBRARGMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10682419-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180147291-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147291-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, VIP, PEPD | NR1H4 870/4885EPHX2 112/4885RARA 3889/4885 |
| US-10682419-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | PREP, VIP, PEPD | NR1H4 870/4885EPHX2 112/4885RARA 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.